• 1
    Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea cycle disorders. N Engl J Med 2007; 356: 2282-2292.
  • 2
    Lampher BC, Gropman A, Chapman KA, Lichter-Konecki U, Urea Cycle Disorder Consortium, Summar ML. Urea cycle disorders overview. 2012.
  • 3
    Gropmann A, Fricke S, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, et al. 1H MRS identifies symptomatic and asymptomatic patients with partial ornithine transcrbamylase deficiency. Mol Gen and Metab 2008; 95: 21-30.
  • 4
    Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009; 66: 96-101.
  • 5
    Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991; 29: 147-150.
  • 6
    Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010; 100: 221-228.
  • 7
    McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. HEPATOLOGY 2010; 51: 2077-2085.
  • 8
    Lichter-Konecki U, Diaz GA, Merritt JLII, Feigenbaum A, Jomphe C, Marier JF, et al. Ammonia control in children with urea cycle disorders (UCDs); Phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011; 103: 323-329.
  • 9
    Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, LeMons C, et al. Establishing a consortium for the study of rare diseases: the Urea Cycle Disorders Consortium. Mol Genet Metab 2010; 100( S1): S97-S105
  • 10
    National Urea Cycles Disorder Foundation. 2012;
  • 11
    Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Lutz, FL: Psychological Assessment; 2000 (original version), 2003 (preschool version), 2005 (adult version).
  • 12
    Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Members of the ISHEN Commission on Experimental Models of HE. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783-788.
  • 13
    Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 1992; 121: 259-261.
  • 14
    Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, et al., Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008; 94: 397-402.
  • 15
    Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010; 99: 246-255.
  • 16
    Vockley J, Vockley CM. Clinical trials: curing a critical deficiency in metabolic medicine. Mol Genet Metab 2010; 99: 244-245.